Autoplaque vs Eko Low Ejection Fraction Tool (ELEFT)
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if you require detailed, quantitative analysis of coronary artery plaque and luminal stenoses from CT angiography images. This tool is ideal for cardiologists and radiologists seeking to precisely characterize atherosclerotic disease, predict heart attack risk, and guide treatment strategies based on advanced imaging data.
View Autoplaque →Choose Eko Low Ejection Fraction Tool (ELEFT) if…
Choose Eko Low Ejection Fraction Tool (ELEFT) if you need a rapid, non-invasive screening tool for early detection of low ejection fraction during routine physical exams. This AI-powered solution is best suited for primary care physicians and cardiologists looking to quickly identify patients at risk of heart failure using digital stethoscopes, facilitating timely referrals for further diagnostic workup.
View Eko Low Ejection Fraction Tool (ELEFT) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Low Ejection Fraction Tool (ELEFT)Tool B (ELEFT) offers higher general usability by integrating AI into routine physical exams with digital stethoscopes, providing rapid, non-invasive results in approximately 15 seconds. This contrasts with Tool A (Autoplaque)'s workstation-based, specialized post-processing workflow, which is more complex and tailored for expert users in radiology and cardiology.
Clinical Value
TieBoth tools provide significant clinical value in distinct areas of cardiac care and are FDA-cleared. Tool A (Autoplaque) offers detailed quantitative analysis of coronary plaques and stenoses from CT angiography for heart attack risk prediction and treatment guidance. Tool B (ELEFT) aids in the early, non-invasive detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.
Pricing & Value
Eko Low Ejection Fraction Tool (ELEFT)Tool B (ELEFT), while requiring contact for specific pricing, benefits from established CMS reimbursement rates for its SENSORAu2122 platform, offering a clearer understanding of its economic value for healthcare providers. In contrast, Tool A (Autoplaque) has not disclosed any pricing information, making its value proposition less transparent.
Enterprise Readiness
Eko Low Ejection Fraction Tool (ELEFT)Tool B (ELEFT) demonstrates superior enterprise readiness with its cloud-based deployment, explicit HIPAA compliance, and Business Associate Agreement (BAA). As part of Eko's SENSORAu2122 platform, it offers enterprise features like single sign-on, an admin dashboard, and dedicated customer success management, which are crucial for large-scale implementation. Tool A (Autoplaque) is workstation-based and lacks specified HIPAA compliance or BAA.
Innovation
TieBoth tools showcase significant innovation in their respective domains. Tool A (Autoplaque) innovates in advanced cardiac imaging analysis by providing AI-powered quantitative analysis and characterization of coronary plaque from CT angiography. Tool B (ELEFT) innovates by integrating AI into digital stethoscopes for rapid, non-invasive, point-of-care detection of low ejection fraction.
Support & Docs
Eko Low Ejection Fraction Tool (ELEFT)Tool B (ELEFT) provides more documented support resources, including user manuals and a help center, and offers dedicated customer success managers and VIP customer support for its enterprise platform. While some customer reviews mention challenges with Eko's general customer service, Tool A (Autoplaque) has no specific support or documentation details provided in the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Name | Autoplaque | Eko Low Ejection Fraction Tool (ELEFT) |
| Company | Cedars-Sinai Medical Center: AIM | Eko Health |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | The Eko Low Ejection Fraction Tool (ELEFT) is an FDA-cleared AI algorithm that integrates with Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams. |
| Key Features | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area | AI-powered low ejection fraction detection; Integrates with FDA-cleared Eko digital stethoscopes; Analyzes ECG and heart sound recordings; Provides results in approximately 15 seconds; Part of the SENSORAu2122 Cardiac Early Detection Platform; Cloud-based data processing and storage; Aids in early identification of heart failure risk; Non-invasive screening tool |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and Eko Low Ejection Fraction Tool (ELEFT).
Frequently Asked Questions
More Comparisons
More matchups featuring Autoplaque or Eko Low Ejection Fraction Tool (ELEFT)
Backers
Who funded each tool's parent company.